Not a chance.
Wrong again. You may want to brush up on some business principles. The money comes from improving health and safety. Supposedly that is what drugs are for.
If the motives are for purely health and safety, then why doesn't Harvard release the license to the public? Don't pretend that there are shining knights involved in this mess.
Now you are calling a court of law unjust and bribable.
That is ridiculous, I never said anything like that.
The courts are upholding the law. Patent infringers are always trying to pretend that their motives are honest and true while they try to steal the intellectual property of others for the sole motive of making money.
Amgen could try and run DNAPrint into bankrupcy, though. Or on the flip side, they could buy PT-401.
If Amgen wanted PT-401 they could have it. They could have bought it from Harvard, they could pay up the back license fees and take it over now, or they could buy DNAG for what they currently spend on free cafeteria cofee for their employees. Amgen is obviously not the least bit interested.
The value of PT-401 has been well established. No one legitimate wants it. It is only fodder for the illegitimate extraction of wealth from the investor base.
regards,
frog
News 
Market Data 
Discover 
AI
